Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia

Venetoclax along with hypomethylating agents (HMAs) is the new standard therapy for older patients acute myeloid leukemia (AML) not fit intensive frontline induction chemotherapy. associated fatal episodes of tumor lysis syndrome (TLS) in chronic lymphocytic (CLL), and recommendations are its initiation CLL AML inpatient setting close monitoring. Herein, we evaluated safety outpatient venetoclax ramp up when given addition to HMAs treatment AML. We conducted a retrospective review diagnosed at our institution from 12/1/2016 until 7/1/2020. identified who received AML, either as or relapsed/refractory therapy. Records were reviewed evidence laboratory clinical all patients. Between 7/1/2020 43, venetoclax/HMA Thirty-nine (91%) had setting. One episode TLS (2.5%) was identified. This patient required admission hospital rasburicase IV fluids resolution effects without resultant TLS. There no group. Thirty-day mortality 0% both groups. Our experience showed that safe very low risk within cohort.